CN104640567A - 治疗或预防牙周炎和与牙周炎相关的疾病的方法 - Google Patents

治疗或预防牙周炎和与牙周炎相关的疾病的方法 Download PDF

Info

Publication number
CN104640567A
CN104640567A CN201380032526.1A CN201380032526A CN104640567A CN 104640567 A CN104640567 A CN 104640567A CN 201380032526 A CN201380032526 A CN 201380032526A CN 104640567 A CN104640567 A CN 104640567A
Authority
CN
China
Prior art keywords
periodontitis
compound
activation
expression
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380032526.1A
Other languages
English (en)
Chinese (zh)
Inventor
乔治·哈吉申加利斯
约翰·D·兰贝瑞斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn
Publication of CN104640567A publication Critical patent/CN104640567A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/18—Dental and oral disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
CN201380032526.1A 2012-06-20 2013-06-19 治疗或预防牙周炎和与牙周炎相关的疾病的方法 Pending CN104640567A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261662022P 2012-06-20 2012-06-20
US61/662,022 2012-06-20
US13/801,096 US9579360B2 (en) 2012-06-20 2013-03-13 Methods of treating or preventing periodontitis and diseases associated with periodontitis
US13/801,096 2013-03-13
PCT/US2013/046599 WO2013192319A1 (en) 2012-06-20 2013-06-19 Methods of treating or preventing periodontitis and diseases associated with periodontitis

Publications (1)

Publication Number Publication Date
CN104640567A true CN104640567A (zh) 2015-05-20

Family

ID=49769337

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380032526.1A Pending CN104640567A (zh) 2012-06-20 2013-06-19 治疗或预防牙周炎和与牙周炎相关的疾病的方法

Country Status (8)

Country Link
US (2) US9579360B2 (cg-RX-API-DMAC10.html)
EP (1) EP2863949B1 (cg-RX-API-DMAC10.html)
JP (1) JP6363595B2 (cg-RX-API-DMAC10.html)
CN (1) CN104640567A (cg-RX-API-DMAC10.html)
AU (1) AU2013277217B2 (cg-RX-API-DMAC10.html)
CA (1) CA2877299C (cg-RX-API-DMAC10.html)
IN (1) IN2015DN00438A (cg-RX-API-DMAC10.html)
WO (1) WO2013192319A1 (cg-RX-API-DMAC10.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2753636T (pt) 2011-09-07 2020-01-21 Univ Pennsylvania Análogos de compstatina com propriedades farmacocinéticas melhoradas
US9579360B2 (en) * 2012-06-20 2017-02-28 The Trustees Of The University Of Pennsylvania Methods of treating or preventing periodontitis and diseases associated with periodontitis
EP3110423A4 (en) 2014-02-25 2017-09-20 Achillion Pharmaceuticals, Inc. Ether compounds for treatment of complement mediated disorders
BR122021025449B1 (pt) 2014-06-12 2024-02-15 Ra Pharmaceuticals, Inc Composto, polipeptídeo e composição compreendendo o mesmo
WO2016123371A1 (en) 2015-01-28 2016-08-04 Ra Pharmaceuticals, Inc. Modulators of complement activity
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
WO2017035409A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
JP6968787B2 (ja) 2015-10-07 2021-11-17 アペリス・ファーマシューティカルズ・インコーポレイテッドApellis Pharmaceuticals, Inc. 投与レジメン
ES2941640T3 (es) 2015-12-16 2023-05-24 Ra Pharmaceuticals Inc Moduladores de la actividad del complemento
MX2019006527A (es) 2016-12-07 2019-08-01 Ra Pharmaceuticals Inc Moduladores de la actividad del complemento.
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
CA3053818A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
WO2019028284A1 (en) 2017-08-02 2019-02-07 Achillion Pharmaceuticals, Inc. THERAPEUTIC REGIMES FOR THE TREATMENT OF NOCTURNAL PAROXYSTIC HEMOGLOBINURIA
SG11202005181RA (en) 2017-12-04 2020-07-29 Ra Pharmaceuticals Inc Modulators of complement activity
AU2018386304B2 (en) 2017-12-15 2023-12-07 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
JP7423070B2 (ja) 2018-04-06 2024-01-29 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 増加した溶解度および改善された薬物動態特性を有するコンプスタチンアナログ
CN112839945A (zh) 2018-09-06 2021-05-25 艾其林医药公司 补体因子d抑制剂的形态形式
WO2020051532A2 (en) 2018-09-06 2020-03-12 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
CN112996497A (zh) 2018-09-25 2021-06-18 艾其林医药公司 补体因子d抑制剂的形态形式
KR20210104071A (ko) 2018-12-17 2021-08-24 아칠리온 파르마세우티칼스 인코포레이티드 보체 매개 장애의 치료를 위한 표적 투약
US20220160820A1 (en) 2019-03-08 2022-05-26 Ra Pharmaceuticals, Inc. Modulators of complement activity
AU2020245434A1 (en) 2019-03-22 2021-09-30 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement mediated disorders
CA3134614A1 (en) 2019-03-29 2020-10-08 Ra Pharmaceuticals, Inc. Complement modulators and related methods
WO2020219822A1 (en) 2019-04-24 2020-10-29 Ra Pharmaceuticals, Inc. Compositions and methods for modulating complement activity

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270365A (en) 1991-12-17 1993-12-14 Merck & Co., Inc. Prevention and treatment of periodontal disease with alendronate
US5627264A (en) * 1994-03-03 1997-05-06 Alexion Pharmaceuticals, Inc. Chimeric complement inhibitor proteins
JP2001294536A (ja) * 2000-04-12 2001-10-23 Sunstar Inc 歯周病予防・治療剤
US20050169921A1 (en) * 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
CA2608116A1 (en) * 2005-05-10 2006-11-16 Intermune, Inc. Method of modulating stress-activated protein kinase system
PL2148691T3 (pl) * 2007-02-05 2015-12-31 Apellis Pharmaceuticals Inc Analogi kompstatyny do stosowania w leczeniu stanów zapalnych układu oddechowego
WO2010056399A1 (en) * 2008-11-17 2010-05-20 Incode Biopharmaceutics, Inc. Method and composition for modulating the immune system and various inflammatory conditions comprising complement depletors
NO2424557T3 (cg-RX-API-DMAC10.html) * 2009-05-01 2018-03-24
WO2010132954A1 (en) 2009-05-21 2010-11-25 Oral Health Australia Pty Ltd Method of treating periodontal disease by administering antagonists of par-2
JP5675821B2 (ja) * 2009-09-23 2015-02-25 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレート Ｔｏｌｌ様受容体モジュレーター及びその使用
EP2525814A4 (en) 2010-01-22 2013-09-11 Univ Louisville Res Found METHODS OF TREATING OR PREVENTING PERIODONTITIS AND PARODONTIST-RELATED DISEASES
WO2011115225A1 (ja) * 2010-03-17 2011-09-22 国立大学法人 鹿児島大学 歯周病特異的ペプチド、並びにそれを用いた歯周病の治療および診断
AU2012272706B2 (en) * 2011-06-22 2017-07-06 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
PT2753636T (pt) * 2011-09-07 2020-01-21 Univ Pennsylvania Análogos de compstatina com propriedades farmacocinéticas melhoradas
US9579360B2 (en) * 2012-06-20 2017-02-28 The Trustees Of The University Of Pennsylvania Methods of treating or preventing periodontitis and diseases associated with periodontitis

Also Published As

Publication number Publication date
CA2877299C (en) 2022-07-12
US10668135B2 (en) 2020-06-02
AU2013277217A2 (en) 2015-01-22
EP2863949A1 (en) 2015-04-29
IN2015DN00438A (cg-RX-API-DMAC10.html) 2015-06-19
AU2013277217A1 (en) 2015-01-22
JP6363595B2 (ja) 2018-07-25
US20170202935A1 (en) 2017-07-20
EP2863949A4 (en) 2016-03-02
CA2877299A1 (en) 2013-12-27
EP2863949B1 (en) 2019-01-23
WO2013192319A1 (en) 2013-12-27
US9579360B2 (en) 2017-02-28
AU2013277217B2 (en) 2018-03-08
JP2015523999A (ja) 2015-08-20
US20130344082A1 (en) 2013-12-26

Similar Documents

Publication Publication Date Title
JP6363595B2 (ja) 歯周炎および歯周炎に関連する疾患を処置または予防する方法
Maekawa et al. Genetic and intervention studies implicating complement C3 as a major target for the treatment of periodontitis
Hajishengallis et al. Complement-dependent mechanisms and interventions in periodontal disease
Abe et al. Local complement-targeted intervention in periodontitis: proof-of-concept using a C5a receptor (CD88) antagonist
US20170246269A1 (en) Methods of treating or preventing periodontitis and diseases associated with periodontitis
Hajishengallis et al. Complement inhibition in pre-clinical models of periodontitis and prospects for clinical application
Xiao et al. FOXO1 deletion reduces dendritic cell function and enhances susceptibility to periodontitis
Schenkein et al. Cytokines and inflammatory factors regulating immunoglobulin production in aggressive periodontitis.
US20140302027A1 (en) Methods of treating periodontal inflammation and periodontal bone loss
Tang et al. Dasatinib and Quercetin Mitigate Age‐Related Alveolar Bone Inflammaging and Neutrophil Infiltration
Perayil et al. Comparison of the efficacy of subgingival irrigation with 2% povidone-iodine and tetracycline HCl in subjects with chronic moderate periodontitis: A clinico microbiological study
JP5108068B2 (ja) 口腔内の細菌群を改善するラクトバシラス・ファーメンタムＳＧ−Ａ９５（ＬａｃｔｏｂａｃｉｌｌｕｓｆｅｒｍｅｎｔｕｍＳＧ−Ａ９５）及びその保健組成物
Ye et al. Periodontitis aggravates pulmonary fibrosis by Porphyromonas gingivalis-promoted infiltration of neutrophils and Th17 cells
WO2015175512A1 (en) Compositions and methods of regulating bone resorption
WO2010132954A1 (en) Method of treating periodontal disease by administering antagonists of par-2
Aihara et al. Levels of IL-17, RANKL and OPG in Gingival Crevicular Fluid Obtained from Patients with Severe Orthodontic Root Resorption
Lohner The Role of HDAC6 in Periodontal Inflammation
Yu Role of interleukin-17 signaling in acute periodontal disease
Dede et al. Evaluation of IL-32 levels in gingival tissue and serum of experimental periodontitis model
Chen et al. Non‐Syndromic Hereditary Gingival Fibromatosis Driven by Chymase Deficiency Is Attenuated by Verteporfin‐Loaded Exosomes
Zambrano Pacheco et al. Use of Probiotics as Adjuncts in Non-Surgical Periodontal Therapy: A Literature Review
Gaitán Fonseca et al. Lifestyle and relationship with periodontal disease
Pacios Pujadó Cellular mechanisms that affect periodontal destruction induced by bacteria infection in diabetic and non diabetic rats
Ergun Oral Aspects of Sjögren’s Syndrome
Ergun Oral Aspects of Sjogren’s Syndrome

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150520